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1 |  DIABETES AND DIABETIC 
KIDNEY DISEASE
1.1 | Diabetes and its complications
Diabetes is a heterogeneous group of diseases characterized 
by chronic hyperglycemia. It has classically been divided 
into type 1 (T1D) and type 2 diabetes mellitus (T2D) and 
a few rare forms of the disease. T1D is characterized by lit-
tle or no production of insulin by the pancreatic beta‐cells, 
whereas T2D is characterized by both impaired insulin secre-
tion and insulin resistance, leading to the inability of insu-
lin‐sensitive muscle and adipose tissues to take up glucose. 
Chronic hyperglycemia leads to damage of blood vessels and 
consequently, diabetes is associated with both macrovascular 
and microvascular complications that are major causes for 
morbidity and mortality.1 The macrovascular complications 
include coronary artery disease, peripheral arterial disease 
and stroke, and the microvascular complications include dia-
betic kidney disease, neuropathy and retinopathy.1
1.2 | Diabetic kidney disease
This review concentrates on diabetic kidney disease (DKD), 
the potentially life‐threatening complication of diabetes and 
the most common cause of chronic kidney disease in the de-
veloped world. As the incidence of diabetes is escalating, also 
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Abstract
SHIP2 (Src homology 2 domain‐containing inositol 5′‐phosphatase 2) belongs to the 
family of 5′‐phosphatases. It regulates the phosphoinositide 3‐kinase (PI3K)‐medi-
ated insulin signalling cascade by dephosphorylating the 5′‐position of PtdIns(3,4,5)
P3 to generate PtdIns(3,4)P2, suppressing the activity of the pathway. SHIP2 mouse 
models and genetic studies in human propose that increased expression or activity of 
SHIP2 contributes to the pathogenesis of the metabolic syndrome, hypertension and 
type 2 diabetes. This has raised great interest to identify SHIP2 inhibitors that could 
be used to design new treatments for metabolic diseases. This review summarizes 
the central mechanisms associated with the development of diabetic kidney disease, 
including the role of insulin resistance, and then moves on to describe the function 
of SHIP2 as a regulator of metabolism in mouse models. Finally, the identification 
of SHIP2 inhibitors and their effects on metabolic processes in vitro and in vivo are 
outlined. One of the newly identified SHIP2 inhibitors is metformin, the first‐line 
medication prescribed to patients with type 2 diabetes, further boosting the attraction 
of SHIP2 as a treatment target to ameliorate metabolic disorders.
K E Y W O R D S
diabetes, diabetic kidney disease, insulin resistance, insulin signalling, lipid phosphatase, podocyte
2 of 22 |   LEHTONEN
the number of patients suffering from DKD is increasing.2 
DKD is characterized by gradual increase in albumin excretion 
into urine, a decrease in glomerular filtration rate, elevated ar-
terial blood pressure and development of glomerulosclerosis. 
It develops to 20%‐40% of patients with T1D and to even up to 
50% of patients with T2D.3 The development of DKD is mul-
tifactorial involving hyperglycemia‐induced metabolic and 
hemodynamic processes that are further influenced by genetic 
and environmental factors. The non‐modifiable risk factors 
include genetics, sex, age at onset and duration of diabetes.3 
Also a number of modifiable factors, including glycemic con-
trol, blood pressure, lipid abnormalities, smoking, chronic 
low‐grade inflammation, advanced glycation end products and 
lack of physical activity, affect the development of DKD.3
The pathophysiological changes in the kidney upon de-
velopment of DKD involve both the tubular and glomerular 
compartments as well as the vasculature. An early feature of 
DKD is kidney hypertrophy, occurring in both glomerular 
and tubular compartments.4 The greatest hypertrophic change 
is observed in the proximal tubules. The growth of the tubules 
and enhanced Na+‐glucose cotransport lead to increased prox-
imal tubule reabsorption and an increase in the glomerular 
filtration rate through tubuloglomerular feedback.4 Increased 
exposure to different diabetes‐associated metabolites may 
trigger various pathological pathways associated with tubu-
lointerstitial fibrosis, inflammation, hypoxia and apoptosis 
that may contribute to the progression of DKD.4
1.3 | Changes in the glomerular filtration 
barrier in DKD
Glomerulus is the central site of kidney injury in diabetes. 
Podocytes, the highly specialized epithelial cells, form to-
gether with the fenestrated endothelial cells and the glomer-
ular basement membrane (GBM) the glomerular filtration 
barrier that prevents the passage of proteins of the size of 
albumin and larger from the capillary lumen to the urinary 
space while allowing water and small molecules to freely pass 
(Figure 1A). Podocytes wrap around the capillaries, with their 
large cell bodies extending to the urinary space, and their foot 
processes attaching to the underlying GBM. The neighbour-
ing podocyte foot processes are interconnected by special 
cell adhesion structures called slit diaphragms (Figure 1B,C), 
composed of a set of transmembrane proteins and cytosolic 
adapter molecules linking the slit diaphragm to the underly-
ing actin cytoskeleton and signalling networks.5 One of the 
central molecules of the slit diaphragm is the immunoglobu-
lin superfamily member nephrin, shown to be essential for an 
intact glomerular filtration barrier as mutations in it lead to 
the congenital nephrotic syndrome of the Finnish type.6 The 
compartmentalization of the apical and basolateral domains of 
the podocytes by the slit diaphragm allows the expression of 
distinct sets of proteins in a polarized manner. As an example, 
podocalyxin is expressed in the apical domain of podocytes 
and with its negative charge, created by a glycocalyx, appar-
ently maintains the glomerular filtration barrier open.7 More 
detailed molecular characterizations of podocytes and the slit 
diaphragm are provided in recent reviews.5,8
The diabetic milieu, exposing glomerular cells to high 
glucose, fatty acids, growth factors, cytokines and hormones, 
leads to glomerular hypertrophy and distinct changes in the 
structure and function of the glomerular filtration apparatus 
(Figure 1A,B). Histologically, DKD is characterized by me-
sangial matrix expansion and eventually glomerulosclerosis. 
At the electron microscopic level, the first sign of DKD is the 
thickening of the GBM. This is followed by effacement of 
the podocyte foot processes, loss of slit diaphragms and loss 
of podocytes by detachment or apoptosis, and progressive al-
buminuria (Figure 1B‐D).9 Podocytes, endothelial cells and 
mesangial cells are engaged in multidirectional crosstalk (il-
lustrated in Figure 1A), and this has been shown to affect the 
development and progression of DKD, involving a number of 
pathways, as summarized below.
1.4 | Podocyte‐mesangial cell axis in DKD
A central contributor to glomerular damage is hyperglycemia‐
induced activation of the intrarenal renin‐angiotensin‐aldos-
terone system (RAAS) and production of excess angiotensin 
II.10 Angiotensin II can damage podocytes, endothelial cells 
and mesangial cells by activating pathways associated with 
extracellular matrix accumulation, fibrosis, inflammation 
and generation of reactive oxygen species (ROS).10 Increased 
generation of intracellular ROS leads to podocyte apopto-
sis.11 Podocyte loss is deleterious as podocytes are terminally 
differentiated cells and they lack the capacity to proliferate. 
The absolute number of podocytes can predict the progres-
sive decline in renal function and proteinuria12; when po-
docyte loss exceeds 40%, sustained high‐grade proteinuria 
ensues and renal function declines.13
A central regulator of the synthesis of extracellular ma-
trix proteins is transforming growth factor beta (TGF‐β), 
produced by mesangial cells.14 TGF‐β‐induced stimuli 
contribute to glomerular basement membrane thickening, 
mesangial matrix production and loss of podocytes.14 TGF‐β‐ 
induced podocyte loss may occur via apoptosis15 caused by 
activation of the mammalian target of rapamycin (mTOR) 
pathway, stimulation of mitochondrial oxidative phosphory-
lation and generation of ROS.16 TGF‐β may also induce de-
tachment of viable podocytes via epithelium‐to‐mesenchyme 
transition (EMT),17 that is, by inducing downregulation of 
epithelial and upregulation of mesenchymal proteins, which 
may lead to podocyte detachment.17 Podocyte apoptosis may 
also be caused by hyperglycemia‐induced generation of ad-
vanced glycation end products (AGEs), which induce gen-
eration of intracellular ROS.18 Also reduction of autophagy, 
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F I G U R E  1  Glomerular filtration barrier and changes observed in diabetic milieu. A, A schematic cartoon of the glomerulus in health 
and in diabetic milieu. The cartoon also depicts the crosstalk (black, curved arrows in diabetic milieu) between podocytes and endothelium (1), 
endothelium and podocytes (2) and mesangial cells and podocytes (3). Ang‐1/2, angiopoietin‐1/2; ET‐1, endothelin‐1; GBM, glomerular basement 
membrane; TGF‐beta, transforming growth factor beta; VEGF, vascular endothelial growth factor. The black arrows indicate size‐ and charge‐
selective filtration of plasma through the glomerular filtration barrier in health. Red arrows indicate leakage of albumin (albuminuria) through the 
damaged glomerular filtration barrier in diabetic milieu. B, A schematic cartoon of the glomerular filtration barrier and factors associated with 
the indicated changes in diabetic kidney disease. The glomerular filtration barrier consists of three layers, the endothelial cells with glycocalyx, 
the glomerular basement membrane (GBM) and the podocytes, with their foot processes interconnected with slit diaphragms. In diabetic milieu, 
the glomerular filtration barrier shows distinct changes associated with the development of albuminuria. These changes include glomerular 
basement membrane thickening, podocyte foot process and endothelial cell effacement, loss of slit diaphragms and endothelial glycocalyx, and 
detachment or apoptosis of podocytes. Examples of the factors involved in these changes are indicated. AGEs, advanced glycation end‐products; 
ROS, reactive oxygen species. C‐D, Electron microscopic images visualizing the glomerular filtration barrier in health and in diabetic kidney 
disease. C, An electron micrograph of the glomerular filtration barrier in a healthy mouse. The inset shows a higher magnification of the filtration 
barrier. Arrowheads indicate slit diaphragms. D, An electron micrograph of the glomerular filtration barrier in a mouse model of diabetes (E1‐DN 
mouse; the image is similar to fig. 6b,c in21), showing irregular thickening and bulging of the GBM and foot process effacement. cl, capillary loop; 
E, endothelial cell; FP, foot process; GBM, glomerular basement membrane; us; urinary space; asterisk, GBM thickening and bulging; arrow, 
podocyte foot process effacement; arrowhead, slit diaphragm. Scale bar in C and D, 2 µM
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the lysosomal degradation pathway that maintains cellular 
homoeostasis, leads to podocyte apoptosis.19,20 Of the slit 
diaphragm proteins, nephrin, for example, has been shown 
to be either downregulated21,22 or mislocalized23,24 in animal 
models of DKD, and the apical domain protein podocalyxin 
has been shown to be downregulated in the kidneys of dia-
betic rats.25 These changes contribute to podocyte foot pro-
cess effacement and loss of slit diaphragms. As visualized by 
the above examples, a multitude of mechanisms contribute to 
podocyte injury and dysfunction (summarized in Figure 1B), 
as described in more detail in recent reviews.26,27
1.5 | Endothelial cell‐podocyte axis in DKD
Abnormal angiogenesis and endothelial cell damage in glo-
meruli are also central contributors to the development of 
DKD. New blood vessel formation has been observed in 
both T1D and T2D, and this contributes to glomerular hy-
pertrophy in the early stages of diabetic kidney injury.28,29 
Morphological studies have revealed a reduction in glomer-
ular capillary endothelial fenestrations and damage of the 
endothelial glycocalyx (Figure 1B).30-32 The proangiogenic 
factor vascular endothelial growth factor (VEGF) plays a key 
role in abnormal angiogenesis in the glomeruli in diabetes, 
and its expression correlates with new blood vessel forma-
tion in glomeruli.33 VEGF isoforms VEGFA and VEGFC are 
both produced by podocytes and their receptors are expressed 
in endothelial cells.34,35 The expression of both VEGFA and 
its receptor, VEGF receptor 2, is increased in experimental 
diabetes.36 VEGFA is associated with glomerular endothe-
lial cell damage and vascular dysfunction but interestingly, 
various VEGFA isoforms confer differing effects on the kid-
ney.37 In line with this, a recent study revealed that upregu-
lation of VEGFA165b isoform in mouse podocytes in vivo 
protects against diabetic kidney injury and albuminuria by 
phosphorylating VEGF receptor 2 in endothelial cells and 
restoring the endothelial glycocalyx damaged by diabetes.37 
In experimental diabetes, VEGFC enhances the synthesis of 
endothelial glycocalyx and reduces albumin permeability in 
glomeruli, and thereby reduces the development of diabetic 
kidney injury.38 While animal experiments have suggested 
promise for antiangiogenic therapies, and especially for 
anti‐VEGF antibodies for treating DKD, findings in human, 
demonstrating development of renal injury and proteinuria as 
summarized in a recent review,39 have raised a concern about 
blocking VEGF signalling. Concomitantly, it appears that ei-
ther too much or too little of VEGFA can lead to pathological 
changes in the kidney.39 Interestingly, inhibition of VEGFB 
signalling in experimental DKD models appears to protect 
against DKD—via non‐angiogenic mechanisms—by ame-
liorating renal lipotoxicity and thereby reducing pathological 
changes in the kidney, sensitizing podocytes to insulin and 
preventing renal dysfunction.40
The actions of VEGF are modulated by angiopoietin‐1, 
which is expressed in podocytes, while its receptor Tie2 is found 
in glomerular endothelium.41 In experimental diabetes, angio-
poietin‐1 level is decreased concomitant to increased VEGFA 
and signs of diabetic kidney injury, including aberrant angio-
genesis.42 Some of these changes, including proliferation of en-
dothelial cells and albuminuria, could be reverted by targeted 
overexpression of angiopoietin‐1 in podocytes.42 Furthermore, 
the expression of angiopoietin‐2, a natural antagonist of angio-
poietin‐1 signalling,43 was shown to be upregulated in podo-
cytes and glomerular endothelial cells in an experimental model 
of diabetes concomitant with low expression of angiopoie-
tin‐1.44 As podocyte‐specific overexpression of angiopoietin‐2 
causes apoptosis of endothelial cells,45 the reduced angiopoi-
etin‐1/angiopoietin‐2 ratio may be a contributing factor in the 
development of DKD.44 A recent study revealed increased mi-
tochondrial dysfunction specifically in glomerular endothelial 
cells, but not in podocytes, in experimental streptozotocin‐in-
duced diabetes in a mouse strain susceptible to diabetic kidney 
injury.46 The endothelial cells of these mice showed signs of 
injury and loss of fenestrae at an early stage of the disease. The 
mice also showed podocyte loss and albuminuria, and increased 
expression of endothelin‐1 receptor type A in the glomeruli, 
and increased circulating endothelin‐1.46 Notably, reducing mi-
tochondrial stress pharmacologically or blocking endothelin‐1 
receptor type A reduced injury of the endothelial cells and ame-
liorated podocyte loss and albuminuria.46
Crosstalk between the different cell types is also essential 
in the tubulointerstitial compartment and may play an import-
ant role in renal disease progression.47 More detailed discus-
sion on the crosstalk between the different renal cell types is 
beyond the scope of this review, but the given examples un-
derscore the complexity of the regulation of the glomerular 
filtration and emphasize the role of all glomerular cell types in 
maintaining the normal kidney function, as well as in contrib-
uting to the dysfunction of the filtration barrier in renal dis-
eases, including DKD. The topic of glomerular cell crosstalk 
has been extensively covered by several recent reviews.47-50
1.6 | Mitochondrial dysfunction and 
hypoxia in DKD
The function of mitochondria and health of kidney are closely 
interlinked due to high energy and oxygen demands of the 
kidney, and thereby mitochondrial dysfunction is considered 
as a central contributor to the development and progression 
of DKD.51-53 Mitochondria regulate the levels of reactive 
oxygen species (ROS), cytosolic calcium and apoptosis and 
produce ATP for basic cellular functions as well as for cellu-
lar repair. An experimental model of diabetes in rat revealed 
decreased ATP content and fragmentation of mitochondria in 
proximal tubule cells prior to the onset of proteinuria, sup-
porting a role for mitochondrial dysfunction as a driver in the 
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development of DKD.54 While low levels of ROS, such as 
superoxide anions, are beneficial for cellular functions, ex-
cessive generation of ROS is a general sign of mitochondrial 
dysfunction in the kidney and toxic to the mitochondria and 
the cells.51,52 Oxidative stress contributes to increased apop-
tosis and fibrosis, leading to declined renal function. A recent 
study revealed that inhibition of apoptosis signal‐regulating 
kinase 1 (ASK1), which induces apoptotic, fibrotic and in-
flammatory signalling in states of oxidative stress, reduces 
inflammation and fibrosis and prevents the reduction of the 
glomerular filtration rate in rodent models of DKD.55 This 
supports the hypothesis of beneficial effects of reducing oxi-
dative stress in DKD. Another recent study searched for fac-
tors that protect from DKD and found that pyruvate kinase 
M2 (PKM2), a glycolytic enzyme, was elevated in patients 
with over 50  years duration of diabetes without signs of 
DKD.56 Activation of PKM2 in rodent models of diabetes 
normalized metabolic parameters and mitochondrial dys-
function and ameliorated kidney pathology, suggesting that 
increasing the glycolytic flux and mitochondrial biogenesis 
protects glomeruli from the toxicity caused by hypergly-
cemia.56 Mitochondrial function has also been linked with 
insulin signalling.57 The researchers showed that podocyte‐
specific depletion of mitochondrial fusion‐associated protein 
prohibitin‐2 (PHB2) in mice results in proteinuria, renal fail-
ure and death of the animals.57 Strikingly, however, deple-
tion of PHB2 in mice and cultured podocytes indicated that 
despite of the morphological changes of the mitochondria, 
the oxidative phosphorylation system was not impaired and 
also the oxygen consumption of podocytes lacking PHB2 
remained normal. However, depletion of PHB2 resulted in 
insulin receptor‐mediated hyperactivity of mTOR signalling. 
In line with this, knocking out insulin receptor either alone 
or in combination with IGF‐1 receptor in mice depleted of 
PHB2 delayed the onset of renal failure without affecting 
the mitochondrial phenotype. The triple knockout animals 
remained proteinuric, though, indicating that an mTOR‐in-
dependent pathway regulates the proteinuria.57 Nevertheless, 
this study provides compelling evidence interconnecting mi-
tochondrial dysfunction and insulin signalling, and empha-
sizes the importance of maintaining the activity of the insulin 
signalling cascade at an appropriate level.
Mitochondrial function and ROS production together 
with increased oxygen consumption are intimately linked to 
tissue hypoxia.53,58 In diabetes, hyperglycemia increases the 
oxygen demand of the kidney and when not matched with 
increased oxygen delivery, intrarenal hypoxia emerges.59 
Concomitantly, Franzén et al.60 measured intrarenal oxy-
gen tension in diabetic mice, revealing that kidney hypoxia 
precedes albuminuria. This suggests that improving oxy-
gen homoeostasis in the kidney could provide a way to treat 
DKD. Of note, however, specific targets may have highly 
cell‐specific consequences. Activating, for example, hypoxia 
inducible factor (HIF) in kidney tubules is beneficial for 
mitochondrial function and protects the kidney, whereas 
HIF activation in glomeruli leads to glomerulosclerosis and 
proteinuria.58 Altogether, the maintenance of mitochondrial 
homoeostasis, that is, mitochondrial biogenesis, fission and 
fusion as well as elimination of damaged, non‐functional mi-
tochondria, is essential for maintaining normal kidney func-
tion.51 Studies have revealed that several antidiabetic drugs 
affect various mitochondrial functions independent of their 
hypoglycemic effects, including both protective and harmful 
effects, as highlighted by a recent review.61
1.7 | Endoplasmic reticulum stress in DKD
Various diabetes‐associated factors, including hypergly-
cemia, proteinuria and increased levels of free fatty acids 
and advanced glycosylation end products, contribute to the 
development of endoplasmic reticulum (ER) stress that 
advances the progression of DKD.62,63 ER stress markers 
have been shown to be upregulated in the kidneys of ex-
perimental animals as well as of patients with T2D.63 In 
DKD, protein misfolding and ER stress are evident in both 
podocytes and the tubular compartment, and can lead to 
apoptosis and extracellular matrix production.62 The 78‐
kDa glucose‐regulated protein (GRP78) is a classical ER 
chaperone and a central regulator of protein folding pro-
cesses, and, thus, it plays a key role in maintaining protein 
homoeostasis.64 A recent study revealed that high glucose 
treatment induces translocation of GRP78 to the plasma 
membrane in mesangial cells, where it binds to integrin 
β1, activates focal adhesion kinase and the downstream 
PI3K/AKT signalling.64 This enhances the synthesis of ex-
tracellular matrix proteins and glomerular fibrosis.64 Also 
other studies have linked insulin signalling to ER stress in 
diabetes. Madhusudhan et al.65 found that impaired insu-
lin signalling together with hyperglycemia prevents the 
nuclear translocation of transcription factor spliced X‐box 
binding protein 1 (sXBP1), which resulted in maladap-
tive ER stress signalling in podocytes and worsened DKD. 
Concomitantly, the same team found that coagulation pro-
tease activated protein C (aPC) maintains ER homoeosta-
sis via sXBP1 in podocytes.66 Specifically, they revealed 
that aPC can compensate for the absence of insulin recep-
tor in podocytes in mice with experimental diabetes. This 
occurred by activation of the PI3K p85‐subunit‐dependent 
nuclear translocation of sXBP1, which prevented the mala-
daptive ER stress.66
1.8 | Epigenetic changes in DKD
In addition to transcription factors and classical signalling cas-
cades, genes associated with DKD are regulated by epigenetic 
mechanisms.67 Epigenetic changes do not alter the underlying 
6 of 22 |   LEHTONEN
DNA sequence but affect the accessibility of chromatin and 
expression of genes via DNA methylation, chromatin histone 
modifications and non‐coding RNAs. Environmental factors 
play a key role in the development of DKD, and the epigenetic 
mechanisms mediate the crosstalk between the genes and the 
environment. Epigenetic changes are also apparently involved 
in the so called metabolic memory, in which the gene expres-
sion pattern induced by high glucose persists even though the 
glycemic control has been achieved.67 The emerging develop-
ments in the epigenetic research in DKD may open new therapy 
options for DKD. A recent study revealed increased expression 
of DNA methyltransferase 1 in peripheral blood mononuclear 
cells in patients with DKD.68 This altered the methylation of the 
promoter regions of the regulators of the mTOR signalling path-
way, leading to activation of the pathway and increased inflam-
mation in the diabetic kidneys.68 Majumder et al.69 showed that 
modifying histone methylation in podocytes affects the course 
of glomerular diseases. They found that histone H3 lysine 27 
trimethylation (H3K27me3) is diminished and the expression 
of demethylase UTX is increased in patients with DKD. This 
induces dedifferentiation of podocytes and accelerates the de-
velopment of glomerular injury. Concomitantly, inhibiting the 
demethylase in diabetic db/db mice ameliorated kidney disease, 
further supporting the hypothesis that targeting the epigenetic 
events may be beneficial in treating DKD.69
1.9 | Insulin signalling in DKD
Understanding the complexity of the molecular and cellular 
interaction networks and the exact molecular mechanisms 
involved in renal cell crosstalk will aid in designing new in-
tervention strategies to slow down or stop the progression 
of renal diseases. At the same time, it has become apparent 
that the heterogeneous nature of diabetes makes treating it 
challenging, and the available treatment strategies often fail 
to stop the progression of the disease and its complications. 
Many of the studies above point out the potential of target-
ing a specific molecule or certain cellular modifications to 
prevent the development of DKD, yet we lack the personal-
ized treatment options, called for due to the complex nature 
of the disease. A recent study describes a data‐driven cluster 
analysis of six variables in patients with newly characterized 
diabetes. The authors identified five clusters of patients with 
diabetes, each subgroup specified by distinct disease progres-
sion and risk of diabetic complications. Interestingly, one of 
the clusters, the patients most resistant to insulin, showed a 
high risk to develop DKD.70 In addition, previous studies 
have revealed that insulin resistance is associated with micro-
albuminuria in patients with either T1D71 or T2D72,73 as well 
as in healthy people without diabetes,74 and that insulin resist-
ance precedes and predicts the development of both microal-
buminuria and nephropathy in T1D.75,76 These data highlight 
the importance of insulin signalling in maintaining normal 
kidney function and insulin resistance as a central contribu-
tor to the development of kidney disease and albuminuria. It 
is also interesting to note that several of the mechanisms that 
participate in driving the development of DKD, as presented 
in the paragraphs above, converge with the insulin signalling 
pathway, further underlining the importance of this pathway 
as a central contributor to kidney health.
2 |  DEFECTS IN INSULIN 
SIGNALLING AND GLUCOSE 
TRANSPORTER TRAFFICKING 
LEAD TO THE DEVELOPMENT OF 
INSULIN RESISTANCE
Understanding the mechanisms leading to the development 
of insulin resistance is essential as insulin resistance is a key 
factor in the pathogenesis of diabetes and DKD, as described 
above.70,77 Development of insulin resistance is caused by ei-
ther reduced activity of the insulin signalling cascade or im-
paired trafficking of the insulin responsive glucose transporter 
4 (GLUT4) to the plasma membrane.78 Insulin signalling is 
initiated by binding of insulin to insulin receptor leading to 
its activation, the consequent phosphorylation of a number of 
downstream substrates and activation of the phosphatidylino-
sitol 3‐kinase (PI3K) pathway (Figure 2A). PI3K phospho-
rylates phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) 
to phosphatidylinositol 3,4,5‐trisphosphate (PtdIns(3,4,5)P3), 
which is a key lipid second messenger in various metabolic 
effects of insulin. To enhance glucose uptake, PtdIns(3,4,5)
P3 transfers signals to downstream molecules including ser-
ine/threonine kinase Akt.78 In the basal state, GLUT4 resides 
mainly in the cytoplasm and only a small proportion is de-
tected at the plasma membrane, but insulin‐induced activa-
tion of Akt induces rapid translocation of GLUT4‐containing 
vesicles to the cell surface.79,80 The trafficking is controlled 
at various steps with distinct sets of proteins. Specifically, the 
GLUT4‐containing vesicles contain vesicle‐SNAREs (solu-
ble N‐ethylmaleimide‐sensitive factor attachment protein re-
ceptors), which interact with target‐SNAREs on the plasma 
membrane. These together, further aided by sets of accessory 
proteins, facilitate the translocation, docking and fusion of the 
GLUT4‐containing vesicles with the plasma membrane lead-
ing to uptake of glucose into cells (Figure 2A).79,80
Defects either in the insulin receptor itself, for example, 
changes in its expression level or activity, in its downstream 
substrates or molecular regulators of the signalling cascade 
may lead to impaired activation of the insulin signalling 
pathway and insulin resistance (Figure 2A).78 However, the 
numbers of individuals with genetic defects in the insulin 
receptor are rare, proposing that peripheral insulin resis-
tance is rather caused by defects downstream of the insulin 
receptor. It is plausible that the cause of insulin resistance 
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is multifactorial, a combination of genetic defects and envi-
ronmental factors, or that it is caused by simultaneous lower 
functional input of multiple components of the pathway, 
which in the end is insufficient to lead to full activation of 
the signalling cascade and uptake of glucose into cells.78 
The complex regulation of the trafficking of GLUT4‐con-
taining vesicles via various accessory molecules at differ-
ent steps makes also the trafficking process a potential site 
for alterations, which may lead to impaired translocation of 
GLUT4 to the plasma membrane and consequent insulin 
resistance (Figure 2A).79,80
3 |  INSULIN RESISTANCE AND 
DIABETIC KIDNEY DISEASE
3.1 | Insulin resistance of podocytes and 
DKD
The seminal study by Ahlqvist et al.70 shows that peripheral 
insulin resistance plays a central role in the development of 
DKD, but it has remained open whether insulin resistance of 
podocytes could directly contribute to the disease progres-
sion. Studies in animal models of diabetes and DKD, supple-
mented by studies on cultured podocytes, have revealed that 
podocytes can develop insulin resistance. Podocytes express 
all the central components of the insulin signalling pathway as 
well as glucose transporters GLUT4 and GLUT1, both shown 
to be insulin responsive in podocytes, and can increase their 
glucose uptake upon insulin stimulation.81 Subsequent stud-
ies revealed that podocytes isolated from diabetic db/db mice 
show reduced level of Akt activation compared to their lean 
controls. Also podocytes isolated from the db/db mice, before 
the mice had developed albuminuria, were unable to phospho-
rylate Akt in response to insulin stimulation.82 The indication 
that insulin resistance of podocytes drives kidney dysfunction 
was provided by a study revealing that knocking out insulin 
receptor specifically in podocytes in mice leads to the devel-
opment of DKD even under normoglycaemia.83 These mice 
showed typical structural features of DKD, including thick-
ening of the GBM, podocyte foot process effacement, signs 
of podocyte loss by apoptosis and glomerulosclerosis and 
started developing albuminuria at 5 weeks of age.83 A recent 
F I G U R E  2  SHIP2 regulates the 
insulin signalling pathway. A, Simplified 
cartoon of the insulin signalling pathway 
indicating various points of regulation of its 
activity. Binding of insulin to its receptor 
leads to activation of phosphatidylinositol 
3‐kinase (PI3K), phosphorylation of 
phosphatidylinositol 4,5‐bisphosphate 
(PI(4,5)P2) to phosphatidylinositol 3,4,5‐
trisphosphate (PI(3,4,5)P3) and subsequent 
activation (phosphorylation, P) of Akt. This 
leads to translocation of insulin responsive 
glucose transporter 4 (GLUT4) to the 
plasma membrane and uptake of glucose 
into cells. The activity of the pathway can 
be modulated at the level of (1) the insulin 
receptor and insulin receptor substrate 
(IRS) proteins, (2) phosphorylation/
dephosphorylation of phosphatidylinositols 
and (3) exocytosis or (4) endocytosis of 
GLUT4. Examples of proteins regulating the 
different steps in podocytes are indicated. 
B, SHIP2 suppresses the insulin signalling 
pathway by hydrolysing PI(3,4,5)P3 to 
PI(3,4)P2. This reduces glucose uptake
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study utilizing cultured podocytes revealed that high concen-
trations of insulin lead to downregulation of insulin receptor 
via proteasome‐dependent lysosomal degradation pathway, 
and this leads to insulin resistance of podocytes.84
3.2 | Regulation of insulin signalling 
in podocytes
Several proteins that regulate the activity of the insulin signal-
ling pathway and glucose uptake in podocytes have been iden-
tified, and examples of them, and the steps they functionally 
control, are presented in Figure 2A. At the level of the insulin 
receptor (Figure 2A, step 1), the protein tyrosine phosphatase 
Src homology‐2 domain containing phosphatase‐1 (SHP‐1), 
that is upregulated by high glucose, suppresses insulin signal-
ling by dephosphorylating insulin receptor‐β.85 Another regu-
lator of the insulin receptor is protein tyrosine‐phosphatase 
1B (PTP1B). Inhibition of PTP1B was shown to have anti‐
diabetic effects by improving insulin and leptin signalling in a 
model of diet‐induced obesity.86 Furthermore, knocking down 
PTP1B activates the PI3K pathway and protects podocytes 
from endoplasmic reticulum (ER) stress, which associates 
with podocyte apoptosis and proteinuria in DKD.87 Activated 
insulin receptor phosphorylates its downstream mediators in-
sulin receptor substrates 1 and 2 (IRS1, IRS2). In podocytes, 
insulin activates IRS2 rather than IRS1.88 Irs2‐depleted podo-
cytes show insulin resistance, which is caused by upregulation 
of a protein called phosphatase and tensin homolog deleted 
on chromosome 10 (PTEN). PTEN dephosphorylates the 
3′‐position of PtdIns(3,4,5)P3 to generate PtdIns(4,5)P2, and 
consequently, upregulation of PTEN diminishes phosphoryl-
ation of Akt and reduces the activity of the insulin signalling 
pathway (Figure 2A, step 2). Knockdown of PTEN leads to 
phosphorylation of Akt and thus activation of the pathway. 
However, instead of protecting from ER stress, as in the case 
of PTP1B, this sensitizes podocytes to ER stress and apopto-
sis reflecting the complexity of the regulation of ER stress in 
podocytes.87 Another lipid phosphatase that regulates insulin 
signalling at the level of phosphoinositides (Figure 2A, step 2) 
is Src homology 2 domain‐containing inositol 5′‐phosphatase 
2 (SHIP2). It acts, similarly as PTEN, on PtdIns(3,4,5)P3, 
but hydolyses its 5′‐position generating PtdIns(3,4)P2 and 
thereby activates the insulin signalling pathway.89 The role 
of SHIP2 as a suppressor of insulin signalling is described in 
more detail in paragraph 4.
3.3 | Regulation of glucose transporter 
trafficking in podocytes
Insulin‐stimulated glucose uptake can be regulated either 
during the exocytosis of the GLUT4 containing vesicles 
(GCVs) from the cytoplasmic pool to the plasma membrane 
(Figure 2A, step 3) or during their endocytosis (Figure 2A, 
step 4) to the endosomal compartment for recycling. For 
exocytosis, GLUT4 needs to be sorted first into GCVs, and 
this is controlled by adapter protein CD2‐associated pro-
tein (CD2AP) in podocytes.90 When CD2AP is missing, 
GLUT4 remains as perinuclear clusters, and insulin‐stimu-
lated glucose uptake is reduced.90 Translocation of GCVs 
to the plasma membrane requires intact actin cytoskeleton, 
and in podocytes, insulin stimulates reorganization of the 
cortical actin cytoskeleton in an insulin receptor‐dependent 
manner.83 The docking and fusion of GCVs with the plasma 
membrane is facilitated by nephrin, which associates with 
the GCV‐protein vesicle‐associated membrane protein 2 
(VAMP‐2).91 Nephrin also associates with the small cy-
toskeletal GTPase septin 7, and the protein complex con-
taining septin 7 plays a central role in controlling the vesicle 
docking and fusion.92-94 It has been proposed that septin 7 
forms a filamentous barrier to hinder GCV translocation to 
the plasma membrane thereby reducing glucose uptake.93 
Depletion of septin 7 enhances the interaction between 
nephrin and VAMP2 to facilitate the docking and fusion 
of GCVs with the plasma membrane, leading to increased 
glucose uptake.93 In addition to nephrin, also non‐muscle 
myosin heavy chain IIA (NMHC‐IIA) and the membrane 
protein SNAP23 are found in the septin 7 complex and, 
interestingly, septin 7 regulates the activity of non‐mus-
cle myosin IIA in this complex.92 Accordingly, depletion 
of septin 7 leads to enhanced activity of non‐muscle myo-
sin IIA in the complex, and this increases GCV docking 
and fusion and uptake of glucose into cells.92 Knockdown 
of NMHC‐IIA or nucleobindin‐2, yet another interaction 
partner of septin 7, both reduce glucose uptake into po-
docytes.92,94 Also phosphorylation of synip on serine 99 
is necessary for GCV translocation and glucose uptake in 
podocytes.95 Thus far, no regulators of GCV endocytosis in 
podocytes have been identified (Figure 2A, step 4).
3.4 | Targeting insulin resistance—a way to 
personalized medication in DKD?
Defining whether podocytes in patients with DKD are insu-
lin resistant is challenging, and the rarity of normoglycae-
mic patients who show insulin resistance and develop DKD 
suggest that development of DKD involves a combination of 
multiple factors in addition to insulin resistance.96 Recent re-
views summarize in more detail the molecular mechanisms 
involved in the development of the kidney complication in 
diabetes, including the role of insulin resistance in the context 
of the insulin signalling and glucose transporters.80,97,98 The 
significance of insulin signalling in maintaining the kidney 
function is supported by intervention studies in both patients 
with diabetes99-101 and experimental animal models of dia-
betes102,103 showing that insulin sensitizers are renoprotec-
tive. These data together support the potential of targeting the 
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components and regulators of the insulin signalling pathway 
as a strategy for developing new therapeutic interventions to 
preserve the kidney function in diabetes. Furthermore, the 
new subclassification of diabetes, identifying insulin resist-
ance as a central risk factor for the development of DKD, 
allows to better predict the disease progression and outcome, 
and to design personalized treatments for patients in each 
subclass, including the severely insulin resistant ones at high 
risk for DKD.104
4 |  SHIP2 SUPPRESSES THE 
INSULIN SIGNALLING PATHWAY
As described above, one of the potential therapeutic target 
molecules that regulates the insulin signalling pathway is the 
lipid phosphatase SHIP2 (Figure 2B). SHIP2 is widely ex-
pressed in different tissues, with high mRNA expression in 
human skeletal muscle, heart and placenta.89 In mouse, SHIP2 
mRNA was detected in all tissues analysed,105 and a LacZ re-
porter gene analysis (LacZ reporter inserted into the Inppl1 
locus) in the Inppl1−/− (SHIP2‐depleted) mice revealed high 
expression of the LacZ reporter in brain, skeletal muscle and 
heart and lower in liver, lung and kidney.106 SHIP1, the close 
homologue of SHIP2 that shares approx. 38% sequence iden-
tity with SHIP2, is expressed mainly in cells of hematopoi-
etic origin and during spermatogenesis.107 SHIP2 has several 
conserved domains, including the NH3‐terminal Src homol-
ogy 2 (SH2) domain, the central 5′‐phosphatase domain and 
the COOH‐terminal proline‐rich and sterile ⍺ motif (SAM) 
domains (Figure 3). The SH2 domain is missing from the 
short isoform of SHIP2, generated by alternative splicing. In 
addition, SHIP2 harbours several tyrosine, serine and threo-
nine phosphorylation sites (reviewed in 108). As SHIP2 sup-
presses the insulin signalling pathway by dephosphorylating 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2,89 leads elevated expression 
level or increased activity of SHIP2 to reduced activation of 
Akt and reduced uptake of glucose into cells (Figure 2B), as 
shown in various cell culture models.109-111 It has been pro-
posed that the catalytic activity of SHIP2 is controlled by its 
tyrosine phosphorylation,112,113 but this has remained con-
troversial and, in addition, it has been proposed that serine 
and threonine phosphorylation could play a role in regulating 
SHIP2 activity.114 The ability of SHIP2 to negatively regulate 
Akt activation necessitates the translocation of SHIP2 to the 
plasma membrane, where its central substrate, PtdIns(3,4,5)
P3, resides.115 In addition to its catalytic phosphatase activ-
ity, SHIP2 has other independent functions mediated via its 
numerous interaction partners. Thereby SHIP2 regulates var-
ious cellular processes, including PI3K‐mediated insulin sig-
nalling, FGF‐ and EGF‐mediated signalling, cell spreading, 
migration and adhesion, actin cytoskeleton dynamics, endo-
cytosis and apoptosis. Mutations in INPPL1 (gene encoding 
SHIP2) have been revealed in opsismodysplasia, a disease of 
bone maturation,116,117 and via its various activities, SHIP2 
associates with many other diseases, including diabetes, can-
cer, atherosclerosis and neurodegenerative diseases (for re-
views, see, for example 108,118,119). This review concentrates 
on SHIP2 in diabetes.
5 |  GENETIC STUDIES OF SHIP2 
IN DIABETES AND DIABETIC 
KIDNEY DISEASE
SHIP2 is encoded by the INPPL1 gene located on human chro-
mosome 11.89 Several genetic studies link SHIP2 to metabolic 
disorders, showing that polymorphisms in INPPL1 may con-
tribute to the pathogenesis of the metabolic syndrome, hyper-
tension and T2D (Table 1). The first piece of evidence was 
provided by finding a mutation (R1142C) in the proline‐rich 
region of the protein in the Goto‐Kakizaki rats, a model for 
T2D, and in spontaneously hypertensive rats, apparently affect-
ing the binding of SH3‐domain containing proteins to this re-
gion.120 Overexpression of the mutated form of SHIP2 in CHO 
cells overexpressing the insulin receptor (CHO‐IR) resulted 
in decreased Akt activation, slightly impairing insulin signal-
ling.120 Further work on patients with T2D identified a patient 
with a 16‐base pair deletion in the 3‐prime untranslated region 
of INPPL1, potentially affecting protein synthesis. Indeed, re-
porter gene studies with the mutated region indicated that the 
deletion results in increased mRNA and protein expression, 
and could thus contribute to increased SHIP2 expression and 
F I G U R E  3  Schematic cartoon of the domain structure of SHIP2 
and SHIP2 inhibitors that have been shown to have metabolic effects. 
The numbers indicate the start and end amino acids of the different 
domains and motifs
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insulin resistance.120 Further analysis of patients with T2D of 
Caucasian origin in the UK and Belgium revealed a significant 
association of the 16‐base pair deletion and T2D, proposing that 
INPPL1 is a candidate gene contributing to the genetic suscep-
tibility of T2D.120 A study in Japanese patients with T2D re-
vealed a number of single nucleotide polymorphisms (SNPs), 
several of which were located in the 5′‐phosphatase catalytic 
region of SHIP2. However, many of the SNPs were detected 
more frequently in the controls than in patients with T2D.121 
In vitro overexpression studies in CHO‐IR cells revealed that 
overexpression of a construct including a particular SNP lo-
cated in the 5′‐phosphatase region inhibited insulin‐induced 
phosphorylation of Akt2 less potently than overexpression of 
wild‐type SHIP2, supporting a protective role for this SNP 
against insulin resistance in this cohort of patients with T2D.121 
Another study in a Japanese cohort identified SNPs in the pro-
moter and 5‐prime untranslated region of INPPL1 and inves-
tigated their association with impaired fasting glycaemia.122 
Overexpression of one of the identified SNPs in cultured cells 
caused an increase in the promoter activity, suggesting that 
SNPs in this region could at least partly account for impaired 
fasting glycaemia at least in the patient cohort in question.122 
SNPs in INPPL1 have also been found to be associated with 
the metabolic syndrome. A study with Finnish patients with 
T1D identified an association of two SNPs in INPPL1 with the 
metabolic syndrome in men,123 and another study on British pa-
tients with T2D found an association of SNPs and haplotypes of 
INPPL1 with hypertension and other components of the meta-
bolic syndrome.124 The metabolic effects of the mutations and 
single nucleotide polymorphisms in INPPL1 are summarized 
in Table 1.
In the above studies, control subjects showed in INPPL1 
SNPs that are protective against T2D. Patients with T2D, on 
the other hand, had in INPPL1 SNPs that are associated with 
and could predispose to the metabolic syndrome, hyperten-
sion and T2D. In studies with mice, SHIP2 protein in diabetic 
db/db mice has been shown to be upregulated in insulin‐sen-
sitive tissues, including skeletal muscle, adipose tissue125 and 
podocytes,126 apparently contributing to insulin resistance. 
Interestingly, SHIP2 was upregulated in podocytes prior to 
the development of albuminuria, and this observation was 
confirmed in insulin‐resistant, obese Zucker fatty rats.126 
These data accord with the genetic studies suggesting a role 
for SHIP2 in the development of insulin resistance and DKD.
6 |  SHIP2 MOUSE MODELS 
SUPPORT A ROLE FOR SHIP2 IN 
METABOLIC DISORDERS
6.1 | SHIP2 knockout mouse models
Both long‐ and short‐term mouse models have been utilized 
to analyse the role of SHIP2 as a regulator of metabolism, in-
cluding both knockout and overexpression strategies (Table 
2). Two different whole‐body knockout mouse models for 
SHIP2 have been generated. The first model targeted exons 
19‐29 of Inppl1 (mouse SHIP2 gene).127 The mice showed 
increased sensitivity to insulin and reduced expression of he-
patic gluconeogenic enzymes, leading to neonatal hypogly-
cemia and death within 3 days after birth.127 Compared to the 
wild type mice, the adult heterozygous mice showed greater 
insulin sensitivity, higher expression of GLUT4 at the plasma 
membrane, and responded to insulin stimulation with higher 
glycogen synthesis rate in the skeletal muscle. However, the 
genomic fraction deleted in this model included not only 
exons 19‐29 of Inppl1, but also the third exon of another gene, 
Phox2a.127 It therefore remains uncertain whether the pheno-
type of the mice is caused by absence of Inppl1, Phox2a or 
both, or by expression of a truncated form of SHIP2.
The second Inppl1 knockout strategy deleted the first 18 
exons of Inppl1 including the translation‐initiating ATG, 
leading to total lack of Inppl1 mRNA and SHIP2 protein.106 
These mice lived till adulthood, but showed truncated fa-
cial features due to abnormal skeletal growth and reduced 
body length and weight, despite a tendency of increased 
food intake. The Inppl1−/− mice showed normal glucose 
and insulin levels as well as normal glucose and insulin 
tolerance, but decreased serum triglycerides, non‐esterified 
T A B L E  1  Mutations and single nucleotide polymorphisms (SNPs) in the SHIP2 gene INPPL1 and their metabolic consequences
SNP/mutation Effect Species Reference
R1142C • Slight impairment of insulin signalling Rat Marion et al.120
16‐bp deletion, 3′‐UTR • Increased SHIP2 expression, association with T2D Human Marion et al.120
L632I • Protection against insulin resistance Human Kagawa et al.121
+334 C/T • Impaired fasting glycemia Human Ishida et al.122
rs2276048
rs2276047
• Association with the metabolic syndrome in men with 
T1D
Human Hyvönen et al.123
snp8
rs2276047
rs9886
• Association with hypertension and other components 
of the metabolic syndrome
Human Kaisaki et al.124
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free fatty acids, cholesterol and leptin levels at 12 weeks of 
age compared to wild‐type littermates. In the basal state, 
Inppl1−/− mice showed no difference in the activation of 
Akt compared to wild‐type mice, but in response to insu-
lin, the null mice showed increased activation of Akt in 
liver and muscle. Interestingly, the null mice gained less 
weight when placed on high‐fat diet for 6 weeks, and did 
not show an increase in serum lipids, insulin or glucose. 
The Inppl1 null mice on high‐fat diet also showed a greater 
basal metabolic rate and increased energy expenditure.106 
T A B L E  2  SHIP2 (encoded by Inppl1) mouse models and their phenotypes. The mouse model generated by Clément et al.127 is not included 
as it remains uncertain whether deletion of Phox2a affects the phenotype
SHIP2 knockout mouse models
Model Generation strategy Phenotype Reference
Inppl1 knockout Deletion of first 18 exons of 
Inppl1
• Developmental defects in skull
• Reduced body length and weight
• Normal glucose and insulin levels
• Normal glucose and insulin tolerance
• Improved serum lipid values
• Resistance to high‐fat diet
Sleeman et al.106
Catalytic inactivation 
of SHIP2
Deletion of exons 18 and 19 of 
Inppl1
• Developmental defects in skull and female genital 
tract
• Reduced skeletal muscle weight and adiposity
• Reduced body weight
• Normal glucose tolerance and insulin sensitivity
• Reduced insulin secretion
• Improved serum lipid values
• Increased proximal tubule reabsorption
Dubois et al.128
Catalytic inactivation 
of SHIP2 in proximal 
tubules
Deletion of exons 18 and 19 of 
Inppl1 in proximal tubules
• Increased proximal tubule reabsorption Sayyed et al.129
catalytic inactivation 
of one SHIP2 allele 
in endothelium
deletion of exons 18 and 19 of 
Inppl1 in endothelium
• Slightly increased body weight
• Higher fasting glucose
• Reduced glucose tolerance and insulin sensitivity
• Blunted acetylcholine‐ and insulin‐mediated aortic 
vasodilatation
• Vascular oxidative stress
Watt et al.130
SHIP2 overexpression mouse models
Model Generation strategy Phenotype Reference
Overexpression of 
wild‐type SHIP2 in 
liver in db/+ mice
Adenovirus‐mediated gene trans-
fer in the liver, 4 d
• Hyperinsulinemia
• Potentiated increase in plasma glucose after oral glu-
cose intake
• Systemic insulin resistance
Fukui et al.131
Overexpression of 5′‐
phosphatase defec-
tive SHIP2 in liver in 
db/db mice
Adenovirus‐mediated gene trans-
fer in the liver, 4 d
• Reduced fasting glucose
• Improvement of elevated glucose and insulin levels 
after oral glucose intake
Fukui et al.131
Overexpression of 5′‐
phosphatase defec-
tive SHIP2 in liver in 
KKAy mice
Adenovirus‐mediated gene trans-
fer in the liver, 5 d
• Reduced gluconeogenesis
• Increased hepatic glycogen content
• Increased glycolysis
• Increased serum triglycerides
• Improved glucose tolerance
• Reduced prandial blood glucose
Grempler et al.132
SHIP2 transgenic 
mice
Overexpression of SHIP2 using 
modified β‐actin promoter
• Increased body weight
• Increased fasting serum insulin
• Impaired glucose tolerance and insulin sensitivity
• Reduced hepatic glycogen content at 9 mo
Kagawa et al.133
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Thus, the lack of Inppl1 protects the mice against diet‐in-
duced obesity.
A more recent study describes generation of a mouse 
model with catalytically inactive SHIP2, deleting exons 18 
and 19.128 These mice had reduced body length and weight, 
defects in the development of the skull and the female gen-
ital tract, and reduced skeletal muscle weight and adiposity. 
Especially, the males were hyperphagic, their serum tri-
glycerides and cholesterol levels as well as insulin secretion 
from the mutant islets were lower. No difference was observed 
in glucose tolerance and insulin sensitivity or signalling,128 
similar to the Inppl1 knockout described above.106 Further 
studies on this model revealed increased microvilli formation 
in the proximal tubules of the kidney due to activation of the 
ezrin/radixin/moesin family of proteins, leading to increased 
reabsorption by the proximal tubules.129 Specifically, reab-
sorption of low‐molecular‐weight proteins, glucose and phos-
phate was increased by the proximal tubule cells. Essentially 
similar kidney phenotype was observed when Inppl1 was cat-
alytically inactivated specifically in proximal tubules only.129 
Interestingly, there was a trend of increased uptake of intra-
venously injected, fluorescently labelled albumin by proxi-
mal tubules after catalytic inactivation of Inppl1 in proximal 
tubules.129 Watt et al.130 generated mice with catalytic inac-
tivation of one Inppl1 allele in endothelium‐specific manner 
to define the role of SHIP2 in vascular function. They found 
that the mice developed increased vascular oxidative stress 
and systemic insulin resistance because of impaired glucose 
uptake in adipose tissue and skeletal muscle. Thus, the study 
proposes that normal vascular SHIP2 is necessary for main-
taining systemic glucose homoeostasis and preventing endo-
thelial dysfunction induced by oxidative stress.130
6.2 | SHIP2 overexpression mouse models
Several studies have addressed the role of SHIP2 in the regu-
lation of metabolism via overexpression strategies, inspired 
by the finding that SHIP2 is upregulated in peripheral insulin 
sensitive tissues in insulin resistant, diabetic db/db mice.125,126 
Transient, adenovirus‐mediated overexpression of wild‐type 
SHIP2 in non‐diabetic db/+ mice led to overexpression of 
SHIP2 in the liver but not in other tissues.131 This decreased 
insulin‐induced activation of Akt in the liver and increased the 
expression of gluconeogenic genes, leading to hyperinsuline-
mia and potentiated the increase in blood glucose after oral 
glucose intake. This indicates that overexpression of SHIP2 
in liver leads to systemic insulin resistance.131 Adenovirus‐
mediated overexpression of 5′‐phosphatase‐defective SHIP2 
(dominant‐negative SHIP2) in diabetic db/db mice improved 
the ability of insulin to induce Akt activation in the liver, and 
partly reduced the enhanced expression of gluconeogenic 
genes.131 This lowered fasting blood glucose and reduced 
elevated glucose and insulin levels after oral glucose intake, 
indicating that inhibition of SHIP2 in liver is effective in ame-
liorating hyperglycemia. Insulin signalling in skeletal muscle 
or adipose tissue was not affected in either model.131 In another 
study, mutated form of SHIP2 lacking the 5′‐phosphatase 
activity was introduced via adenoviral infection into KKAy 
mice, a model of hyperglycemia and hyperinsulinemia.132 
This resulted in increased basal and insulin‐stimulated Akt ac-
tivation in liver, decreased glucose production after puryvate 
challenge, and increased hepatic glycogen content. Hepatic 
SHIP2 inhibition also increased glycolysis and serum tri-
glycerides, improved glucose tolerance and reduced prandial 
blood glucose levels after feeding ad libitum, supporting the 
idea that SHIP2 inhibition improves glucose metabolism.132
In addition to the above two short‐term models, Kagawa et 
al.133 generated transgenic mice overexpressing SHIP2 using 
a modified β‐actin promoter, leading to SHIP2 overexpres-
sion in liver, skeletal muscle, white adipose tissue, pancreas, 
brown adipose tissue and brain. The transgenic mice gained 
more body weight and showed increased fasting plasma insu-
lin, whereas fasting glucose, leptin, adiponectin, total choles-
terol, triglycerides and non‐esterified fatty acids did not differ 
from the wild‐type littermates under normal diet. However, 
the transgenic mice showed impaired glucose tolerance and 
insulin sensitivity. This could be caused by reduced activity 
of the PI3K pathway, as insulin‐stimulated activation of Akt 
was reduced in adipose tissue, skeletal muscle and liver in 
the SHIP2 overexpressing mice. The expression of glucone-
ogenic genes in the liver was increased and glycogen content 
decreased. These data indicate that increased expression of 
SHIP2 impairs glucose metabolism and insulin sensitivity.133
7 |  SHIP2 INHIBITORS 
AMELIORATE METABOLIC 
DISORDERS
The in vitro and in vivo studies described above, revealing 
that SHIP2 overexpression suppresses insulin signalling 
and debilitates glucose metabolism, have increased the in-
terest to develop SHIP2 inhibitors as a potential therapeu-
tic approach to treat obesity‐induced insulin resistance and 
T2D. A number of inhibitors have been identified, but for 
most of them, no data on metabolic effects are available and 
some inhibit also SHIP1 (see discussion on the beneficial 
metabolic effects of SHIP1 inhibition in paragraph 10).134-
138 A few studies describe the effects of SHIP2 inhibition on 
metabolic parameters either in cells in vitro or in vivo.139-142 
Interestingly, we recently identified metformin, the first‐line 
medication used to treat T2D, as a novel SHIP2 inhibitor.140 
The following section focuses on the SHIP2 inhibitors whose 
roles in metabolic disorders have been defined (Figure 3). 
The metabolically less well‐characterized SHIP2 or SHIP1/
SHIP2 inhibitors are summarized in recent reviews.108,119
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7.1 | Small molecule SHIP2 inhibitors
Using malachite green phosphate assay for measuring SHIP2 
activity, Suwa et al.142 screened in a high‐throughput approach 
a chemical library for inhibitors of the phosphatase domain of 
SHIP2. This led to the identification of AS1949490, which 
inhibited human SHIP2 with an IC50 value of 0.62  µmol/L 
and a Ki value of 0.44  µmol/L, but did not inhibit other 
phosphatases, such as SHIP1, PTEN, synaptojanin or myo-
tubularin. In L6 myotubes, AS1949490 increased insulin‐
induced activation of Akt in a dose‐dependent manner, and 
increased both glucose consumption and glucose uptake. In 
FAO hepatoma cells, AS1949490 reduced glucose produc-
tion, and acute administration of the inhibitor to normal mice 
reduced the expression of gluconeogenic genes in the liver. 
Furthermore, administration of AS1949490 to db/db mice for 
7‐10 days reduced both fasting and non‐fasting blood glucose 
and reduced the area under the curve in oral glucose tolerance 
test. This was accompanied by increased phosphorylation of 
GSK3β in the liver, an indication of the activation of insulin 
signalling.142 These findings supported the idea that inhibition 
of SHIP2 has therapeutic potential as a treatment for T2D.
The same group further identified another novel SHIP2 in-
hibitor, AS1938909, with an IC50 value of 0.57 µmol/L and a 
Ki value of 0.44 µmol/L for human SHIP2.141 This inhibitor 
was also highly selective for SHIP2, and increased Akt activa-
tion, glucose consumption and glucose uptake in L6 myotubes. 
Both AS1938909 and the previously identified AS1949490 
increased the expression level of GLUT1 mRNA in L6 myo-
tubes, which could contribute to the increased glucose up-
take.141 The effects of AS1938909 in vivo were not defined.
Ichihara et al.142 utilized in silico ligand‐based drug design 
combining the structures of AS1949490 and NGD‐61338, 
another novel SHIP2 inhibitor with an IC50 value of 
1.1 µmol/L,134 to design new SHIP2 inhibitor candidates.139 
The designed compounds and their derivatives were tested 
for their ability to activate Akt as an indirect measure of 
SHIP2 inhibition. Compound N‐[4‐(4‐chlorobenzyloxy)pyr-
idine‐2‐yl]‐2‐(2,6‐difluorophenyl)‐acetamide (CPDA), the 
most potent of these compounds, was further tested in db/db 
mice. Treatment of the mice with CPDA for 10‐13 days de-
creased the fasting blood glucose, reduced hepatic expression 
of gluconeogenic genes and ameliorated glucose intolerance, 
and the effects were comparable to those of AS1949490.139
7.2 | Antidiabetic drug metformin 
inhibits SHIP2
We utilized in silico structure‐based virtual screening of 
small molecule chemical libraries to identify SHIP2 inhibi-
tors, and one of the identified molecules was metformin.140 
This supports the proposition that metformin not only 
acts via reducing gluconeogenesis in the liver, but also 
enhances insulin sensitivity and glucose uptake in periph-
eral tissues. The early studies on the mechanisms of action 
of metformin revealed that mitochondria are central for 
the effects of metformin in liver.143,144 To produce ATP, 
mitochondria carry out oxidation of NADH, produced by 
glycolysis or β‐oxidation of fatty acids, generating NAD+ 
and electrons. The electrons are transferred through the 
respiratory chain complexes I, II, III and IV to O2, eventu-
ally generating H2O. The protons generated by oxidation 
of NADH are pumped to the intermitochondrial membrane 
through respiratory complexes I, III and IV, and the pro-
ton gradient drives ATP synthase to generate ATP from 
ADP. Metformin has been shown to inhibit the complex 
I (NADH:ubiquinone oxidoreductase) leading to reduced 
cellular respiration.143,144 The reduction in cellular ATP 
concentration and increase in ADP/ATP and AMP/ATP 
ratios activates the energy sensor AMP‐activated protein 
kinase (AMPK). Indeed, Zhou et al.145 revealed that met-
formin activates AMPK and thereby suppresses hepatic 
glucose production and expression of lipogenic enzymes, 
induces fatty acid oxidation, and also enhances glucose 
transport to muscle, leading to reduced plasma glucose and 
triglycerides. Metformin also upregulates PPARγ coacti-
vator 1⍺ (PGC‐1⍺) via AMPK, and selectively downregu-
lates transcription factors that facilitate PGC‐1⍺‐mediated 
gluconeogenesis, thus suppressing gluconeogenesis.146 
Metformin can affect hepatic metabolism also via AMPK‐
independent pathways, as metformin reduced gluconeogen-
esis in mice deficient of AMPK, leading to the proposition 
that metformin inhibits hepatic gluconeogenesis via de-
creased energy state.147 Notably, the effects of metformin 
on AMPK activity are apparently concentration depend-
ent, as low concentrations of metformin, as detected in the 
portal vein, suppressed gluconeogenesis via activation of 
AMPK, without increasing the cellular AMP/ATP ratio.148
Metformin has also been shown to induce the expres-
sion of fibroblast growth factor 21 (FGF21), an endocrine 
hormone with anti‐obesity and anti‐diabetes properties, in 
the liver in AMPK‐independent manner by inhibiting mito-
chondrial complex I.149 Also, metformin‐induced accumu-
lation of AMP abrogates the glucagon‐induced activation 
of adenylate cyclase.150 This leads to reduced level of cy-
clic AMP (cAMP) and reduced activation of protein kinase 
A (PKA) and its targets, and, thus, inhibition of gluconeo-
genesis.150 In addition to affecting mitochondrial complex 
I, metformin has been shown to directly bind to the redox 
shuttle enzyme mitochondrial glycerophosphate dehydro-
genase.151 Inhibition of this enzyme by metformin leads to 
altered hepatic redox state, reduction of the conversion of 
lactate and glycerol to glucose, and reduced hepatic gluco-
neogenesis.151 However, the finding that metformin causes 
an acute inhibition of glycerophosphate dehydrogenase has 
recently been challenged.152 In addition, metformin exerts 
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some of its beneficial metabolic effects via altering the gut 
microbiota by affecting genes encoding metalloproteins or 
metal transporters,153 another facet of the multiple modes 
of action of the drug.
As introduced above, in the liver the only direct tar-
get of metformin is glycerophosphate dehydrogenase,151  
although this has been challenged.152 SHIP2 represents the 
second direct molecular target identified for metformin.140 
In in vitro experiments with purified recombinant proteins, 
metformin was found to directly bind to and inhibit the cat-
alytic activity of the recombinant SHIP2 phosphatase do-
main with an IC50 value of 6.0 µmol/L, but it did not inhibit 
SHIP1 or PTEN confirming the specificity of metformin for 
SHIP2.140 Metformin also inhibited the activity of SHIP2 
in cultured L6 myotubes and podocytes and increased glu-
cose uptake in both cell types. In L6 myotubes, metformin 
increased the amount of GLUT4 at the plasma membrane 
by inhibiting endocytosis of GLUT4 and thereby enhanced 
glucose uptake, without affecting Akt activity. In vivo, 
metformin inhibited SHIP2 activity in muscle and kidney 
tissue of db/db mice after 12 days of treatment. This short‐
term metformin treatment enhanced insulin sensitivity of 
the db/db mice, visualized by reduced glucose area under 
the curve in insulin tolerance test, but hyperglycemia was 
not reduced. This could be due to the compensatory gluco-
neogenesis in the kidney.140 Even though the major site of 
metformin action has previously shown to be inhibition of 
gluconeogenesis in the liver,154 and the 12‐day metformin 
treatment reduced the expression of gluconeogenesis genes 
in the liver, metformin did not inhibit the activity of SHIP2 
in cultured hepatoma cells or in the liver of db/db mice.140 
It thus appears that metformin has tissue‐specific direct tar-
gets, mitochondrial glycerophosphate dehydrogenase in the 
liver151 (see, however152) and SHIP2 in muscle and kidney 
tissue.140 In addition to direct binding to SHIP2, various 
other indirectly activated pathways have been shown to be 
involved in metformin‐induced glucose uptake in muscle 
tissue and as in liver, they occur via both AMPK‐dependent 
and ‐independent mechanisms. For example, metformin has 
been shown to activate atypical protein kinase C (aPKC) via 
AMPK‐, ERK‐ and PDK1‐dependent pathway to enhance 
glucose uptake in muscle.155 A later study revealed that 
metformin increases glucose uptake independent of AMPK 
via novel and conventional PKC isoforms.156 Metformin 
has also been shown to increase the abundance of GLUT1 
at the plasma membrane157 and to decrease GLUT4 endo-
cytosis in muscle cells.140,158
One of the challenges in metformin research has been the 
great variability in experimental concentrations and treat-
ment times, making comparisons between studies difficult. 
Of note, cells in culture tend to lose the receptors via which 
metformin enters the cells.159 Therefore, the concentra-
tions of metformin required in the in vitro experiments may 
greatly vary depending on the cell type, whether the line is a 
primary cell line or an immortalized cell line maintained in 
culture for a long period of time, and on the exposure time 
to metformin.
Collectively, several SHIP2 inhibitors have been iden-
tified but only four of them have been analysed in vitro or 
in vivo and shown to improve metabolic parameters (Figure 
3). Identification of metformin as a SHIP2 inhibitor and the 
findings described above, indicating that SHIP2 inhibition 
improves glucose metabolism, indicate that SHIP2 is an ex-
cellent target to design new treatments to ameliorate insulin 
resistance and T2D.
8 |  DOES SHIP2 CONVEY THE 
RENOPROTECTIVE EFFECTS OF 
METFORMIN?
In addition to its major action in reducing hyperglycaemia, 
metformin has been shown to have renoprotective effects: 
It reduces albuminuria in patients with T2D160,161 and in 
a rat model of T2D,162 and also increases the estimated 
glomerular filtration rate in patients with T1D.163 Various 
mechanisms have been proposed. In rats with T2D, met-
formin increases the expression of nephrin164 and podoca-
lyxin,165 both known to be downregulated or mislocalized 
in DKD.21-24,164,165 Treatment of primary rat podocytes 
with metformin activates protein deacetylase sirtuin 1 
(SIRT1) and AMPK, and prevents high glucose‐induced 
downregulation of SIRT1 expression.166 Metformin also 
reduces high glucose‐induced apoptosis of podocytes in 
vitro.167 Interestingly, podocyte loss was found to be more 
pronounced in patients with T2D receiving non‐metformin 
medication as compared to patients receiving metformin or 
people without diabetes, supporting a renoprotective role 
for metformin.140 This, coupled to the finding that SHIP2 
activity is elevated in the kidneys of patients with T2D 
receiving other than metformin medication proposes that 
metformin could protect podocytes from injury via inhibit-
ing SHIP2 activity.140 This proposition was supported by in 
vitro studies on immortalized human podocytes, in which 
SHIP2 overexpression has been shown to enhance apoptosis 
coupled with reduced Akt activation.126 Metformin restored 
SHIP2 overexpression‐induced reduction in Akt activation 
and normalized the level of apoptosis.140 An earlier study 
revealed that upregulation of SHIP2 in podocytes in dia-
betic animal models occurred already before the reported 
age of onset of proteinuria, and before any histological 
changes in the glomeruli were observed.126 This indicates 
that upregulation of SHIP2 is not a secondary effect of po-
docyte damage but rather contributes to it, and raises an in-
triguing question whether SHIP2 inhibition at an early stage 
of diabetes could prevent podocyte injury and development 
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of DKD. Answering this question calls for carrying out a 
randomized controlled trial with metformin.
The above examples and the previous paragraph illustrate 
the great complexity of the mechanisms of action of met-
formin. Clearly, more work is necessary to understand the 
exact molecular mechanisms via which metformin acts in dif-
ferent tissues, and specifically, to define the central pathways 
via which metformin acts in patients with T2D in long‐term 
treatments. A great amount of work needs to be carried out 
with the new SHIP2 inhibitors to define their exact mecha-
nisms of action in different tissues, and to identify the poten-
tial SHIP2‐independent mechanisms of action. This will aid 
in the drug development process when designing derivatives 
of the best candidate molecules to further improve their char-
acteristics. The mechanistic understanding of how the inhib-
itor works will also help in identifying the potential adverse 
effects.
9 |  BENEFITS AND CAVEATS OF 
INHIBITING SHIP2
As described in the above paragraph, the effects of SHIP2 
inhibition on metabolic parameters in vitro and in vivo point 
out a clear beneficial role for SHIP2 inhibition in reducing 
insulin resistance and hyperglycemia and improving glu-
cose metabolism.139-142 In addition, SHIP2 inhibition by 
metformin protects podocytes from injury at a stage when 
SHIP2 expression or activity is elevated, such as in DKD,140 
proposing that SHIP2 inhibition could be a potent approach 
to prevent DKD. This is a fascinating aspect as the subgroup 
of T2D‐patients with severe insulin resistance is more sus-
ceptible to develop DKD,70 raising a question whether inten-
sive treatment of these patients with metformin, or in future, 
with more potent SHIP2 inhibitors, could provide an effec-
tive means to prevent the development and progression of 
this fierce complication. Further studies are also needed to 
define whether the renoprotective effects of SHIP2 inhibition 
are due to reduction of general peripheral insulin resistance 
or direct protective effects of SHIP2 inhibition on podocytes.
The genetic mouse models to a large part support a protec-
tive role for reduced expression or lowered catalytic activity 
of SHIP2 against metabolic disorders, with the exception of 
catalytic inactivation of one Inppl1 allele in vasculature.130 
This led to increased oxidative stress, endothelial dysfunction 
and systemic insulin resistance, and the authors raised a con-
cern for SHIP2 inhibition in endothelium.130 Previously, no 
such effects were described in the whole body Inppl1 knock-
out,106 and Watt et al.168 do not speculate what could be the 
reason for such a difference in the metabolic outcome in these 
two models. The studies with SHIP2 inhibitors, described 
above, do not raise concerns on systemic insulin resistance 
but rather report contrary findings. Furthermore, expression 
of catalytically inactive SHIP2 in hepatic HepG2 cells has 
been shown to reduce ROS generation. Also, inhibition of 
SHIP2 with AS1949490 in CD2AP‐deficient podocytes, 
showing increased oxidative stress, reduced ROS genera-
tion.169 Despite this, increased apoptosis, caused by lack of 
CD2AP, was not reduced but aggravated by SHIP2 inhibi-
tion, indicating that when CD2AP is missing, SHIP2 inhibi-
tion may have unexpected consequences.169 Uncovering the 
mechanisms involved calls for further studies using in vivo 
models. The studies in cultured cells or short‐term adminis-
tration of SHIP2 inhibitors in vivo may not reflect the out-
come of long‐term inhibitor administration, and there may 
also be cell‐type specific differences in the effects of SHIP2 
inhibition. Also, the uptake of the various inhibitors to differ-
ent cell types very likely varies, which may result in distinct 
outcomes compared to genetic inactivation of SHIP2. SHIP2 
has also functions that are independent of its catalytic activ-
ity, relying on its protein‐protein interactions.118 It may thus 
be that in certain cases the genetic knockout models produce 
a phenotype that does not directly reflect the outcome of re-
ducing only the catalytic activity of SHIP2 with inhibitors, 
leaving the protein interaction domains still functional.
An interesting beneficial aspect of the catalytic inacti-
vation of SHIP2 in mice, either generally or specifically in 
kidney proximal tubules, is the increased reabsorption ability 
of the proximal tubules.129 The study showed both enhanced 
reabsorption of low‐molecular‐weight proteins as well as a 
trend of increased uptake of injected albumin.129 The authors 
proposed that SHIP2 could represent a new therapeutic target 
for renal Fanconi syndrome, characterized by urinary loss of 
low molecular weight proteins and metabolites due to either 
acquired or inherited dysfunction of proximal tubules.129 The 
authors were able to mimic some of the aspects of the genetic 
model with a SHIP2 inhibitor in cultured cells in vitro,129 
but the effects of SHIP2 inhibition with small molecule in-
hibitors in vivo on proximal tubule structure and functional 
properties await further studies. It will also be interesting 
to define whether SHIP2 inhibition in glomerular diseases 
presenting with increased leakage of albumin, such as DKD, 
show increased tubular uptake of albumin achieved by SHIP2 
inhibition.
SHIP2 inhibition has also been addressed in the field of 
cancer research as a potential treatment for specific types of 
cancer. This is a reflection of a paradigm shift in the can-
cer field as it comes to phosphatases, including SHIP2.135 
Phosphatases were earlier considered rather as tumour sup-
pressors, but the finding that they can activate signalling 
pathways proposes that they could actually be potential 
oncogenes and thereby targets for cancer treatment. In the 
case of SHIP2, its hydrolysis product, PtdIns(3,4)P2, binds 
to Akt more potently than PtdIns(3,4,5)P3.170 Furthermore, 
both PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are required for the 
high‐level activation of Akt.171 It has been proposed that both 
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PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are necessary for cancer 
cell survival and malignancy, and both their absolute amount 
and ratio control cell death.172 In line with this “two PIP hy-
pothesis”, studies revealing SHIP2 as a target to treat can-
cer and showing beneficial effects of SHIP2 inhibitors are 
emerging. In clinical specimens of breast,173 colorectal,136,174 
non‐small cell lung175 and hepatocellular176 cancer, the ex-
pression level of SHIP2 has been shown to be elevated and to 
correlate with decreased patient survival. Beneficial effects 
of SHIP2 inhibition have been proposed in breast135,177 and 
colorectal cancer.136 In gastric cancer specimens, however, 
SHIP2 expression is frequently downregulated, and this en-
hances the malignant behaviour of gastric cancer cells.178 
Accordingly, it appears that the effects of SHIP2 in different 
cells are context dependent. It is important to note, that mice 
that express catalytically inactive SHIP2 survive longer than 
18 months and show no signs of tumour development,128 and 
neither do mice depleted of SHIP2.106 These data increase the 
prospects of SHIP2 as a potential cancer treatment target in 
specific types of cancer in which SHIP2 is overexpressed or 
overactivated. The benefits and caveats of SHIP2 inhibition 
are summarized in Table 3.
10 |  FUTURE PROSPECTS
The SHIP2 inhibition studies carried out thus far with 
AS1949490 and CPDA in vivo in mice have covered rela-
tively short‐term treatments, remaining shorter than 2 
weeks.139,142 The long‐term use of SHIP2 inhibitor met-
formin is safe, except that metformin is contraindicated when 
kidney function is declining. Long‐term treatments of dia-
betic rodent models with AS1949490, CPDA and other new 
SHIP2 inhibitors described above are warranted to confirm 
that these inhibitors per se do not cause harmful side effects. 
New SHIP2 inhibitors with better drug‐like characteristics 
(for example, solubility and bioavailability) than those of the 
previously characterized SHIP2 inhibitors would be welcome 
as leads for drug development. The recent classification of 
patients with diabetes to five distinct groups with specific 
profiles of disease progression and risks for complications70 
offers, for the first time, possibilities for precision medicine 
in diabetes. In terms of the kidney complication, the patients 
who are severely insulin resistant are at high risk to develop 
DKD.70 The potential of SHIP2 inhibitors to act as insulin 
sensitizers highlights their potential to provide new leads for 
personalized medications for this subgroup of patients.
Some of the developed inhibitors are panSHIP inhibitors 
that have been tested in cancer cells,135 but their effects on 
metabolic disorders are thus far uncharacterized. At least in-
hibition of SHIP1 with a SHIP1‐specific inhibitor K118 can 
be highly beneficial, as K118 improves the metabolic param-
eters of diet‐induced obese mice by attenuating inflamma-
tion in the visceral adipose tissue.179 The K118 treatment 
was relatively short, 4 weeks; a longer treatment would be 
needed to confirm that no side effects occur upon time. This, 
and treatment of diabetic rodent models with either panSHIP 
inhibitors or with a combination of SHIP1 and SHIP2 inhib-
itors will be needed to define the possible superiority of the 
combined inhibition over inhibition of each protein alone.
The finding that patients with T2D receiving metformin 
exhibit less podocyte loss than patients with other medica-
tion140 raises several fundamental research lines. To show 
that metformin acts renoprotectively in patients with T2D, a 
randomized controlled trial is needed. The other research line 
to pursue is the identification of SHIP2 inhibitors more po-
tent than metformin, especially in terms of better inhibition 
of SHIP2 in podocytes, followed by defining whether these 
T A B L E  3  Benefits and caveats of inhibiting the catalytic activity of SHIP2. See the text for details and references
Benefits Caveats
General metabolism
• Reduction of insulin resistance and hyperglycemia
• Improvement of glucose metabolism
• Genetic SHIP2 inhibition in endothelium leads to systemic insulin 
resistance
• Many SHIP2 inhibitors lack studies of their effects after long‐term 
administration in vivo
Kidney
• Protection of podocytes from SHIP2 overexpression ‐induced  
apoptosis in vitro
• Reduced podocyte loss in patients with T2D receiving metformin 
compared to patients receiving other medication
• Increased solute reabsorption by proximal tubules
• Increased apoptosis of SHIP2 inhibitor ‐treated CD2AP‐deficient 
podocytes in vitro
Cancer
• Potential for treatment of specific types of cancer
• No reports on cancer development in knockout mice or  
mice expressing catalytically inactive SHIP2
• Effects in different cell types are context dependent
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molecules provide better renoprotection than metformin in di-
abetic animal models with kidney disease. One could envis-
age that highly insulin resistant patients at high risk to develop 
DKD70 would greatly benefit from treatments targeting SHIP2 
with an inhibitor enhancing insulin sensitivity as well as pro-
tecting kidneys from injury. Furthermore, knowing that SHIP2 
is upregulated in several types of cancer and that this correlates 
with decreased patient survival, raises an intriguing question 
whether SHIP2 inhibitors could provide potential means also 
for new personalized treatment options for cancer patients.
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